Health X Platform Q4 FY26 Revenue Surges 34.1% to ₹378 Crore

Health X Platform Limited reported a significant 34.1% year-on-year increase in revenue from operations, reaching ₹378.1 crore for the fourth quarter of FY26. For the full fiscal year 2025-26, the company's revenue stood at ₹1,305.9 crore.

Reader Takeaway: Strong revenue growth and narrowing operating losses are positive, but profitability remains a key watch point.

What just happened

Health X Platform announced its financial results for Q4 FY26 and the full fiscal year FY 25-26. Key highlights include a 34.1% year-on-year rise in Q4 revenue to ₹378.1 crore, and a full-year revenue of ₹1,305.9 crore. The company also saw a reduction in its EBITDA loss for the quarter compared to the previous year.

Why this matters

This strong top-line growth indicates increasing market traction for Health X Platform's offerings. The reduction in EBITDA loss suggests improving operational efficiencies, which is crucial for a company in its growth phase. The management's ambitious target of over 30% CAGR for the next five years signals confidence in its business strategy.

The backstory

Health X Platform operates on a dual-platform model, encompassing both 'SastaSundar' (B2C) and 'Retailer Shakti' (B2B) segments. The company has been focusing on expanding its operational reach and network, including over 62,000 retail pharmacies and a wide SKU range.

What changes now

The company is set to invest in expanding its fulfillment infrastructure with new centers planned in Udaipur, Lucknow, and Patna. This expansion is aimed at improving delivery times and managing operational scale. The focus remains on achieving sustained growth while working towards profitability.

Risks to watch

Despite revenue growth, the company continues to report an EBITDA loss of ₹-20.8 crore and a net loss of ₹-12.9 crore in Q4 FY26. Turning these losses into profits will be a critical challenge. Investors will be watching the execution of expansion plans and their impact on future cash flows and profitability.

Peer comparison

While specific peer data for this filing period is not provided, the company's strategy of focusing on both B2C and B2B segments within the pharmaceutical distribution and retail space is a common approach in the industry. Growth and profitability metrics against key competitors will be important for a fuller comparison.

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹378.1 crore (up 34.1% YoY).
• FY 25-26 Revenue: ₹1,305.9 crore (up 20% YoY).
• Q4 FY26 EBITDA: ₹-20.8 crore (improved from ₹-29.1 crore in Q4 FY25).
• Q4 FY26 Net Profit (PAT): ₹-12.9 crore.
• Working Capital (Mar-26): ₹74 crore.
• Inventory Days: Approx. 34 days.
• Management Guidance: Targeting 30%+ CAGR for the next 5 years.

What to track next

Investors should monitor the company's progress in achieving its stated growth targets, its ability to convert operational improvements into net profitability, and the successful rollout of its new fulfillment centers. Tracking inventory management and working capital efficiency will also be key.